Welcome back. As Oracle shares skyrocket and they are up more than 40% still, co-founder Larry Ellison is seeing a huge surge in his wealth, a historic surge. Our Robert Frank with the details, Robert, as we try to figure out who's the richest man on the planet, Elon Musk or Larry Ellison.Well, Sarah, it is now official according to Bloomberg. We do have a new number one world's richest man, Larry Ellison posting the biggest one-day wealth gain in history overnight. at the Oracle share price adding over $10 ...

PresentationKelly McCarthy All right. Thanks, everybody, for joining us. This is Kelly McCarthy from the Morgan Stanley Healthcare team, and I'm so happy to be here with the Terns Pharma team. I'm here joined by CEO, Amy Burroughs; and Chief Development Officer, Scott Harris. So thank you for joining us. Hopefully, it's been a productive conference for you so far. Before I get started, I'm just going to read a quick research disclaimer. For important disclosures, please see the Morgan Stanley research discl ...

To gain an edge, this is what you need to know today.Eye Popping AI ProjectionsPlease click here for an enlarged chart of Oracle Corp ORCL.Note the following:This article is about the big picture, not an individual stock.  The chart of ORCL stock is being used to illustrate the point.The chart shows the price action in ORCL stock after the company reported earnings.The chart shows ORCL stock is gapping up over 30% as of this writing in the premarket.  It is unusual for the stock of a large company like Orac ...

The companies have proposed the deal as a “merger of equals,” even though Anglo American is worth more than double Teck, as plans include sourcing upper management and board representation roughly equally between the two.The deal would also see company headquarters of what would be known as Anglo Teck move to Vancouver, as proponents look to sell Canada on the benefits of the deal that will attract regulatory scrutiny.“We think this is a hugely compelling opportunity for Canada,” said Teck chief executive J ...

CONCLUDED Stock Market News From Sept. 10, 2025: S&P 500 and Nasdaq Extend Records Last Updated: 5 hours ago There Are More Losers Than Gainers Today. The S&P 500 Is Still on Track for New High. By Karishma Vanjani Less than half of the stocks in the S&P 500 are higher today, yet the index is readying for another record. Customer Center Network The S&P 500 is up 0.5%, while the Dow and Nasdaq are down 0.5% and up 0.4%, respectively. The gain in the S&P 500 comes despite 319, or more than half of its stocks, ...

After years of investments that have weighed on the bottom line, Affirm (AFRM) looks poised to enter a profitable future. In its latest quarter, gross merchandise volume (GMV) rose 43% from the prior year to $10.4 billion. Revenue increased 33% to $876 million. The company attained operating profits for the first time, as CEO Max Levchin has consistently said would happen. New products, such as the Affirm card, saw gross merchandise volume gain 132% to $1.2 billion. The number of active cardholders incre ...

The iShares ESG Select Screened S&P 500 ETF (BATS: XVV ) applies an ESG screen on the S&P 500 and hence does not deviate far from it. So far, the ESG screen has helped generate minor basisI am a stock analyst with over 20 years of experience in quantitative research, financial modeling, and risk management. My focus is on equity valuation, market trends, and portfolio optimization to uncover high-growth investment opportunities. As a former Vice President at Barclays, I led teams in model validation, stress ...

The iShares ESG Select Screened S&P 500 ETF (BATS: XVV ) applies an ESG screen on the S&P 500 and hence does not deviate far from it. So far, the ESG screen has helped generate minor basisI am a stock analyst with over 20 years of experience in quantitative research, financial modeling, and risk management. My focus is on equity valuation, market trends, and portfolio optimization to uncover high-growth investment opportunities. As a former Vice President at Barclays, I led teams in model validation, stress ...

The effort falls well short of banning the ads outright, but could dent sales. ...

Key Takeaways Novartis will acquire Tourmaline Bio for $1.4B, paying $48 per share in cash to shareholders. The deal adds pacibekitug, an anti-IL-6 mAb targeting ASCVD, to Novartis' pipeline,Phase II data showed pacibekitug cut hs-CRP levels by up to 86% with placebo-like safety.Novartis ((NVS) has announced that it will acquire Tourmaline Bio, Inc. ((TRML), a New York-based, publicly traded clinical-stage biopharmaceutical company, for $1.4 billion.The acquisition will add phase III ready candidate pacibek ...